Several novel approaches such as gene therapy9, the application of novel extended half-life FVIII products10,11, as well as, the development of non-factor therapies such as a monoclonal antibody mimicking co-factor activity of FVIII12 have been assessed in recent years in order to prevent, or decrease, the risk of inhibitor formation in hemophilia patients. This evidence concerns the gene F8 and hemophilia.